CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Biology Reports"
DOI: 10.1007/s11033-020-05411-9
Abstract: One of the major barriers in cancer therapy is the resistance to conventional therapies and cancer stem cells (CSCs) are among the main causes of this problem. CD133 as a CSC marker displays stem cell-like… read more here.
Keywords: cd133 sirna; cd133; prostate cancer; cancer ... See more keywords